Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (11-20 of 268) with videos related to

Pageof 27
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Tumor-Agnostic Drug DevelopmentMichael Offin, Dazhi Liu, Alexander Drilon
Translational Lung Cancer Research|July 18, 2017
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?Fernando C Santini, Siddharth Kunte, Alexander Drilon
JCO Oncology Practice|January 12, 2021
<i>ROS1</i> at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug DevelopmentIgor Odintsov, Romel Somwar, Marc Ladanyi, et al.
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancerDavid S Hong, Alexander Drilon, Lori J Wirth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2022
An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung CancersYonina R Murciano-Goroff, Guilherme Harada, Alexander Drilon
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancersDavid S Hong, Alexander Drilon, Lori J Wirth
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
RET mutations in neuroendocrine tumors: including small-cell lung cancerCharles M Rudin, Alexander Drilon, J T Poirier
Oncoscience|May 26, 2017
Targeting RET-rearranged lung cancers with multikinase inhibitorsJoshua K Sabari, Evan D Siau, Alexander Drilon
JCO Precision Oncology|September 28, 2023
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase InhibitorsMarcia S Brose, David S Hong, Alexander Drilon
The Lancet. Oncology|October 3, 2012
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapyAlexander Drilon, Natasha Rekhtman, Marc Ladanyi, et al.
Pageof 27

Showing results (11-20 of 268) with videos related to

Sort By:
Pageof 27
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Tumor-Agnostic Drug DevelopmentMichael Offin, Dazhi Liu, Alexander Drilon
Translational Lung Cancer Research|July 18, 2017
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?Fernando C Santini, Siddharth Kunte, Alexander Drilon
JCO Oncology Practice|January 12, 2021
<i>ROS1</i> at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug DevelopmentIgor Odintsov, Romel Somwar, Marc Ladanyi, et al.
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancerDavid S Hong, Alexander Drilon, Lori J Wirth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2022
An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung CancersYonina R Murciano-Goroff, Guilherme Harada, Alexander Drilon
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancersDavid S Hong, Alexander Drilon, Lori J Wirth
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
RET mutations in neuroendocrine tumors: including small-cell lung cancerCharles M Rudin, Alexander Drilon, J T Poirier
Oncoscience|May 26, 2017
Targeting RET-rearranged lung cancers with multikinase inhibitorsJoshua K Sabari, Evan D Siau, Alexander Drilon
JCO Precision Oncology|September 28, 2023
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase InhibitorsMarcia S Brose, David S Hong, Alexander Drilon
The Lancet. Oncology|October 3, 2012
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapyAlexander Drilon, Natasha Rekhtman, Marc Ladanyi, et al.
Pageof 27